ERYTECH strengthens its intellectual property portfolio Post author:admERY Post published:June 2, 2014 Post category:Newsroom ERYTECH announces the granting of two key patents for its core product eryaspase. You Might Also Like ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL September 28, 2017 ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors November 29, 2021
ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012
ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL September 28, 2017
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors November 29, 2021
